ライフサイエンスコーパス: influenza virus vaccine

1 unmet medical need for a broadly protective influenza virus vaccine.

2 or individuals who received live attenuated influenza virus vaccine.

3 n mice vaccinated with inactivated trivalent influenza virus vaccine.

4 roach for the generation of a more universal influenza virus vaccine.

5 in the neonate in response to an inactivated influenza virus vaccine.

6 f piglets were immunized with an inactivated influenza virus vaccine.

7 rum and mucosal antibodies to an inactivated influenza virus vaccine.

8 ated with the 2019 to 2020 split-inactivated influenza virus vaccine.

9 vaccine(4,5), which is a potential universal influenza virus vaccine.

10 tion, thus setting the stage for a universal influenza virus vaccine.

11 irus and immunization with a live attenuated influenza virus vaccine.

12 y of a novel TLR 7/8 agonist R848-conjugated influenza virus vaccine.

13 d may be the key to developing a "universal" influenza virus vaccine.

14 This knowledge will aid development of a pan-influenza virus vaccine.

15 ent of a hemagglutinin stalk-based universal influenza virus vaccine.

16 red as an antigen for developing a universal influenza virus vaccine.

17 the potential to be utilized as a universal influenza virus vaccine.

18 s revitalized efforts to develop a universal influenza virus vaccine.

19 uenza epidemics and pandemics by inactivated influenza virus vaccine.

20 oach offers a means of generating a bivalent influenza virus vaccine.

21 ne candidates for the production of pandemic influenza virus vaccines.

22 ations for the design of novel modified live influenza virus vaccines.

23 can mount specific immune responses against influenza virus vaccines.

24 elopment of live species-specific attenuated influenza virus vaccines.

25 mutant influenza viruses as live attenuated influenza virus vaccines.

26 pe the humoral immunity generated by current influenza virus vaccines.

27 suggest its potential in development of live influenza virus vaccines.

28 ce of neuraminidase as a target for improved influenza virus vaccines.

29 e design of broadly protective and universal influenza virus vaccines.

30 et in future broadly protective or universal influenza virus vaccines.

31 d for the production of the vast majority of influenza virus vaccines.

32 eath and durability of antibody responses of influenza virus vaccines.

33 l guide the design of the next generation of influenza virus vaccines.

34 ase as a potential target of next-generation influenza virus vaccines.

35 avenues for further development of universal influenza virus vaccines.

36 es will be key to developing next-generation influenza virus vaccines.

37 nance of the HA over the NA in many seasonal influenza virus vaccines.

38 assist in the efforts toward more effective influenza virus vaccines.

39 bute to the further development of universal influenza virus vaccines.

40 ls, bringing us a step closer to "universal" influenza virus vaccines.

41 ded in order to improve the effectiveness of influenza virus vaccines.

42 r development as live attenuated H2 pandemic influenza virus vaccines.

43 are poorly immunogenic compared to seasonal influenza virus vaccines.

44 the safety and efficacy in children of live influenza-virus vaccines.

45 velopment of broadly protective or universal influenza virus vaccines(10-13).

46 anufacturing large quantities of inactivated influenza virus vaccine against potential pandemic strai

47 fluenza pandemic, it is important to prepare influenza virus vaccines against different subtypes and

48 breadth that broadly protective or universal influenza virus vaccines aim to induce.

49 cine modalities, including a live attenuated influenza virus vaccine and inactivated influenza virus

50 as approved the expansion of live attenuated influenza virus vaccine and quadrivalent meningococcal c

51 live attenuated (LAIV) or inactivated (TIV) influenza virus vaccines and compared these to antibody

52 linical development as live attenuated human influenza virus vaccines and induce potent influenza vir

53 bs) derived from B cells induced by numerous influenza virus vaccines and infections, we found mAbs t

54 he utility of currently licensed inactivated influenza virus vaccines and novel protein-based vaccine

55 The preparation of live, attenuated human influenza virus vaccines and of large quantities of inac

56 hat the guinea pig model can be used to test influenza virus vaccines and that the efficiency of tran

57 nd templates for the development of NA-based influenza virus vaccines and therapeutics.

58 essential for guiding design of "universal" influenza virus vaccines and therapeutics.

59 Current influenza virus vaccines are an effective prophylaxis ag

60 Current influenza virus vaccines are annually reformulated to el

61 IMPORTANCE As improved influenza virus vaccines are being developed, the influe

62 IMPORTANCE Standard-of-care influenza virus vaccines are composed of a mixture of an

63 Seasonal influenza virus vaccines are effective when they are wel

64 a B virus infection.IMPORTANCE While current influenza virus vaccines are effective, they are affecte

65 The ability to use swine-origin influenza virus vaccines as a public health tool has bee

66 an respiratory viral infections, and that an influenza virus vaccine based on NS1 live attenuated vir

67 A universal influenza virus vaccine based on the same principles see

68 method for increasing the immunogenicity of influenza virus vaccines by exploiting the natural anti-

69 ve effectiveness of trivalent, cold-adapted, influenza virus vaccine (CAIV-T) in children aged 18 mon

70 ramuscularly and trivalent live cold-adapted influenza virus vaccine (CAIV-T; n=1107) intranasally (i

71 Intranasal immunization with inactivated influenza virus vaccine can provide protective immunity,

72 Seasonal influenza virus vaccines can prevent infection, but are

73 e show that immunization with a single-cycle influenza virus vaccine candidate (S-FLU) results in the

74 The development of an H2 pandemic influenza virus vaccine candidate should therefore be co

75 PR/8/34 to rationally design live attenuated influenza virus vaccine candidates through genome-scale

76 f chimeric H1 haemagglutinin-based universal influenza virus vaccine candidates to induce broadly cro

77 ing multiple conserved antigens as universal influenza virus vaccine candidates.

78 assess their improved potential as universal influenza virus vaccine candidates.

79 BALB/c mice were nasally immunized with influenza virus vaccine combined with CT.

80 stalk-based chimeric hemagglutinin universal influenza virus vaccine constructs to protect against H7

81 Current influenza virus vaccines contain H1N1 (phylogenetic grou

82 coated with a monovalent, split inactivated influenza virus vaccine containing A/Singapore/GP1908/20

83 The development of a universal influenza virus vaccine could abolish the need for this

84 y responses to HA.IMPORTANCE The efficacy of influenza virus vaccines could be improved by enhancing

85 New seasonal influenza virus vaccines currently need to be developed

86 ral escape mutants is critical for universal influenza virus vaccine design.

87 n important consideration during "universal" influenza virus vaccine design.

88 nsequently, the NA is a promising target for influenza virus vaccine design.

89 d as an additional target in next-generation influenza virus vaccine development.We found that antibo

90 A, including PIV5-NA, could improve seasonal influenza virus vaccine efficacy and provide protection

91 ta contribute to host-related differences in influenza virus vaccine efficacy.

92 hanisms can be subverted to improve seasonal influenza virus vaccine efficacy.

93 history play important roles as modifiers of influenza virus vaccine efficacy.

94 of the contribution of neuraminidase (NA) to influenza virus vaccine efficacy.

95 gion is a potential universal group-specific influenza virus vaccine epitope.

96 Influenza virus vaccine expressing alpha-Gal epitopes is

97 ve antibodies, immunization with inactivated influenza virus vaccines failed to do so in the mouse mo

98 An investigational live influenza virus vaccine, FluMist, contains three cold-ad

99 Furthermore, inactivated influenza virus vaccines focus on the induction of syste

100 compatible polymer encapsulating inactivated influenza virus vaccine for insertion and dissolution in

101 entary component in a multiantigen universal influenza virus vaccine formulation that also contains H

102 Each year, new influenza virus vaccine formulations are generated to ke

103 Current influenza virus vaccines have to be closely matched to c

104 Influenza virus vaccines have to be reformulated and rea

105 e immunity to vaccination with a T-dependent influenza virus vaccine; (ii) a CD4-independent pathway

106 for improving the immunogenicity of NA in an influenza virus vaccine.IMPORTANCE Influenza virus infec

107 ve the protective efficacy of an inactivated influenza virus vaccine in a neonatal mouse model.

108 targeted for the development of a universal influenza virus vaccine in humans.

109 results suggest that the efficacy of HA-DNA influenza virus vaccine in mice extends to chickens and

110 Humoral immune responses to influenza virus vaccines in elderly individuals are poor

111 Despite the success of influenza virus vaccines in reducing severe illness, the

112 Vaccination with an inactivated influenza virus vaccine, in contrast, did not prevent gu

113 Efforts to develop a universal influenza virus vaccine include refocusing immunity towa

114 improve the efficacy of the current (killed) influenza virus vaccines include the generation of cold-

115 Universal influenza virus vaccines, including chimeric hemagglutin

116 oadministration of IL-33 with an inactivated influenza virus vaccine increases vaccine efficacy again

117 Current seasonal influenza virus vaccines induce responses primarily agai

118 Conventional influenza virus vaccines induce strain-specific neutrali

119 Live attenuated trivalent influenza virus vaccine induces expansion of CD8+ T cell

120 ome residents received inactivated trivalent influenza virus vaccine intramuscularly and simultaneous

121 We observed that when influenza virus vaccine is injected and an LT-IS patch i

122 Intramuscular administration of inactivated influenza virus vaccine is the main vaccine platform use

123 Development of next-generation influenza virus vaccines is crucial to improve protectio

124 The poor efficacy of seasonal influenza virus vaccines is often attributed to pre-exis

125 Inactivated influenza virus vaccines (IVVs) are used for prevention

126 The live attenuated influenza virus vaccine (LAIV) is preferentially recomme

127 esponses and, in the case of live-attenuated influenza virus vaccines (LAIV), there are safety concer

128 ate safer and more efficient live-attenuated influenza virus vaccines (LAIVs) based on recombinant vi

129 donor virus for FluMist, a live, attenuated, influenza virus vaccine licensed in 2003 in the United S

130 wed hope that the development of "universal" influenza virus vaccines may be within reach.

131 ction provided by the BECC470 adjuvant in an influenza virus vaccine model and shows the enhanced imm

132 demonstrates efficacy in a variety of murine influenza virus vaccine models assaying homologous, hete

133 Improved influenza virus vaccines need to elicit protective immun

134 Due to limitations of current influenza virus vaccines, new vaccines that mediate broa

135 Commercial influenza virus vaccines often elicit strain-specific im

136 hain reactions and sequencing identified the influenza virus (vaccine or wild-type).

137 ern regarding the egg protein content in the influenza virus vaccine, pediatricians have in the past

138 rs of wild-type and pandemic live attenuated influenza virus vaccines (pLAIV) representing four subty

139 IMPORTANCE A self-assembling influenza virus vaccine platform that seamlessly convert

140 We vaccinated mice with formalin-inactivated influenza virus vaccine preparations containing disparat

141 Current influenza virus vaccines primarily aim to induce neutral

142 cacy in macaques of an intrarespiratory live influenza virus vaccine produced by truncating NS1 in th

143 This new system is thus suitable for influenza virus vaccine production and may be applicable

144 ale mortality and morbidity, but traditional influenza virus vaccine production is too slow for rapid

145 Current influenza virus vaccines protect mostly against homologo

146 Development of a universal influenza virus vaccine providing broadly cross-protecti

147 scribe how a recombinant neuraminidase-based influenza virus vaccine reduces transmission in vaccinat

148 ted chimeric haemagglutinin-based, universal influenza virus vaccine regimens elicited cross-reactive

149 Currently licensed influenza virus vaccines rely on the antigenic match of

150 Current influenza virus vaccines rely upon the accurate predicti

151 We conclude that live attenuated pandemic influenza virus vaccines replicate similarly in AGMs and

152 r immunological parameters predict poor anti-influenza virus vaccine responses and can be used as bio

153 ansmissibility and systems-level analyses of influenza virus vaccine responses provide an improved fr

154 ize protection against seasonal and pandemic influenza viruses, vaccines should aim to boost this pre

155 trates that inhibition of PA-X expression in influenza virus vaccine strains may provide a novel way

156 found poor lineage matches with recommended influenza virus vaccine strains.

157 irus hemagglutinin and stalk-based universal influenza virus vaccine strategies are being developed a

158 Current influenza virus vaccine strategies stimulate immune resp

159 rthermore, we recently developed a universal influenza virus vaccine strategy based on chimeric hemag

160 Immunization of ferrets by a universal influenza virus vaccine strategy based on viral vectors

161 oncept of a chimeric hemagglutinin universal influenza virus vaccine strategy that is based on the sa

162 lk domain has become a promising "universal" influenza virus vaccine strategy.

163 IMPORTANCE Universal influenza virus vaccines targeting antigens conserved am

164 ntigens could form the basis for a universal influenza virus vaccine that has the potential to elicit

165 IMPORTANCE The development of a universal influenza virus vaccine that protects against seasonal d

166 As we advance the development of improved influenza virus vaccines that incorporate standard amoun

167 candidates could be developed into universal influenza virus vaccines that protect from infection wit

168 de improved protection from infection, novel influenza virus vaccines that target the conserved epito

169 uman immunization with trivalent inactivated influenza virus vaccine (TIV) only rarely and modestly b

170 ound that the seasonal trivalent inactivated influenza virus vaccine (TIV) or a monovalent vaccine pr

171 ed by reassortment, can be used as safe live influenza virus vaccines to induce a long-lasting protec

172 icity and increase the protective breadth of influenza virus vaccines to reduce the seasonal disease

173 bjects received either trivalent inactivated influenza virus vaccine (TVV) intramuscularly and trival

174 Vaccination with the MF59-adjuvanted influenza virus vaccine was able to induce protective CD

175 rotein is the major immunogenic component in influenza virus vaccines, we sought to restore its expre

176 nduced by an oil-in-water, adjuvanted, whole influenza virus vaccine were previously shown in VAERD-a

177 ctivated influenza virus, or live attenuated influenza virus vaccines were not protected against leth

178 Generation of a universal influenza virus vaccine with the potential to elicit lon

179 ated influenza virus vaccine and inactivated influenza virus vaccines with or without adjuvant, all i

180 NA may help to enhance its immunogenicity in influenza virus vaccines without compromising antibody r

181 A next-generation influenza virus vaccine would provide long-lasting, broa